Straight answers to the concerns people bring to us: what the research shows, what may help, and when to call your clinician.
Nausea, vomiting, diarrhea and constipation
What people hear. GLP-1s make everyone sick.
What the evidence shows. Stomach-related side effects are the most common. In the approved-product trials, nausea affected 44% of people on semaglutide 2.4 mg (16% on placebo) and 25% to 29% on tirzepatide (8% on placebo). Most cases were mild to moderate, happened during dose increases and often eased with time.
What may help. Smaller meals, eating slowly and stopping when you first feel full. Going easier on greasy or very rich foods. Steady fluids, and fiber with fluids for constipation. Clinicians may slow the pace of dose increases.
When to contact a clinician. Vomiting or diarrhea that does not settle, signs of dehydration such as dizziness or very dark urine, or being unable to keep fluids down.
Muscle and lean-mass loss
What people hear. You lose muscle, not fat.
What the evidence shows. Most weight lost in the trials was fat. In body-composition substudies of STEP 1 and SURMOUNT-1, lean mass fell by about 10% while fat mass fell more (about 19% and 34%), so the share of lean mass in the body went up. Scans count water and organ tissue as lean mass too, not only muscle. Some lean-mass loss happens with most significant weight loss, and how much it affects strength and function is still being studied.
What may help. Protein at every meal, regular strength training if it is appropriate for you, and staying active. Your clinician can suggest what fits your health.
When to contact a clinician. Noticeable weakness, falls, or trouble with everyday activities.
Bone density and fractures
What people hear. GLP-1s weaken your bones.
What the evidence shows. Significant weight loss by any method can be accompanied by some loss of bone density, partly because bones carry less load and partly because nutrition and body composition change. In one randomized trial, adults taking the GLP-1 medicine liraglutide alone lost some hip and spine bone density, while those who combined it with regular exercise did not. Bone-density changes are not the same as fractures, and evidence on fracture risk with GLP-1 treatment is limited and mixed.
What may help. Weight-bearing and strength exercise if appropriate, and enough protein, calcium and vitamin D from food or as your clinician recommends.
When to contact a clinician. A history of osteoporosis or fractures, a fall, or new bone pain.
Gallbladder problems
What people hear. GLP-1s cause gallstones.
What the evidence shows. Rapid weight loss itself raises gallstone risk. A 2022 analysis of 76 randomized trials found GLP-1 medicines were linked to a higher relative risk of gallbladder and bile-duct problems (about 37% higher overall), with more risk at higher doses, longer use and weight-loss doses. These events were still uncommon.
What may help. Knowing the warning signs matters most. Tell your clinician if you have had gallstones before.
When to contact a clinician. Pain in the upper right or middle of the abdomen, especially after eating, fever, or yellowing of the skin or eyes. Severe pain needs urgent care.
Pancreatitis
What people hear. GLP-1s cause pancreatitis.
What the evidence shows. Acute pancreatitis is listed as a warning on the labels. Large randomized trials have generally not shown a clear increase, while some observational studies have: a 2023 insurance-claims study of people using GLP-1 medicines for weight loss reported a higher rate than with another weight-loss medicine, though events were rare and the estimate was uncertain. The risk appears uncommon.
What may help. Tell your clinician about any history of pancreatitis, gallstones, heavy alcohol use or very high triglycerides.
When to contact a clinician. Severe, persistent pain in the upper abdomen that may spread to your back, with or without vomiting, needs urgent care.
Delayed stomach emptying and severe stomach symptoms
What people hear. GLP-1s paralyze your stomach.
What the evidence shows. Slowing stomach emptying is part of how these medicines reduce appetite. Severe or persistent symptoms are uncommon but have been reported, and the same 2023 claims study reported higher rates of gastroparesis and bowel obstruction diagnoses, based on small numbers. The labels warn about severe stomach reactions, and the medicines are not recommended for people with severe gastroparesis.
What may help. Small meals and stopping when full. Tell the care team before any surgery or procedure that uses sedation, because food may stay in the stomach longer.
When to contact a clinician. Vomiting that will not stop, being unable to keep food or fluids down, severe bloating or abdominal pain, or no bowel movement with pain.
Hair shedding
What people hear. GLP-1s make your hair fall out.
What the evidence shows. Hair loss was reported slightly more often than with placebo in the approved-product trials: about 3% vs 1% with semaglutide 2.4 mg, and 4% to 5% vs 1% with tirzepatide. Shedding after rapid or large weight loss (telogen effluvium) is a recognized pattern with weight loss of any cause and is usually temporary.
What may help. Enough protein and a balanced diet, gentle hair care, and patience: this kind of shedding usually settles within months.
When to contact a clinician. Heavy or patchy hair loss, or shedding that lasts more than about six months.
Stopping treatment and weight regain
What people hear. The weight all comes back when you stop.
What the evidence shows. Often a good part of it does. One year after stopping semaglutide in the STEP 1 extension, participants had regained about two-thirds of the weight they had lost. In SURMOUNT-4, people switched from tirzepatide to placebo regained about 14% of body weight over the next year, while those who continued kept losing. Obesity behaves like a long-term condition.
What may help. Planning with your clinician for what comes next, and building eating and activity habits during treatment that you can keep.
When to contact a clinician. Before stopping or changing treatment, or if cost or side effects make continuing hard.
The thyroid warning
What people hear. GLP-1s cause thyroid cancer.
What the evidence shows. Semaglutide and tirzepatide carry a boxed warning because they caused thyroid C-cell tumors in rodents. It is not known whether they cause these tumors in people. They are not used in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2).
What may help. Share your personal and family history during intake so the clinician can check.
When to contact a clinician. A lump or swelling in the neck, trouble swallowing, persistent hoarseness or shortness of breath.
General education, not medical advice. Do not change or stop your medication without talking to your clinician. The figures above come from studies of FDA-approved products and doses, not compounded formulations.
